ABVC BioPharma Enhances Silicon Valley Facility as Central Hub for Domestic Pharmaceutical and Functional Food Development

ABVC BioPharma has announced operational enhancements at its BioKey subsidiary's 28,176-square-foot pharmaceutical development and manufacturing facility in Silicon Valley, positioning the site as a central component of the company's global chemistry, manufacturing, and controls strategy. The Fremont, California facility currently incorporates formulation development laboratories, analytical laboratories, quality-aligned production areas, and warehousing, with capacity for expansion to support multiple development programs simultaneously within a single integrated U.S.-based location. The facility operates as a single-location, multi-product development center supporting pharmaceutical formulations, botanical and plant-based products, controlled-release and specialized solid-oral dosage forms, and functional food and nutraceutical products.

All activities from formulation through pilot-scale preparation are performed entirely within the United States, providing a fully domestic development pathway that aims to reduce cross-border complexities and enhance supply-chain resilience for potential partners. BioKey's operational capabilities include formulation development for pharmaceuticals and functional food products, process development and pilot-scale preparation, analytical testing, stability studies, quality documentation, and technical and regulatory support for U.S. and international submissions. This integrated structure enables simultaneous support of multiple therapeutic and nutraceutical projects under coordinated oversight, creating a comprehensive development ecosystem.

The expansion outlook through 2030 represents one of the most significant aspects of this announcement, with ABVC anticipating that BioKey's expanded activities, operational growth, and partner-supported programs will enable and support up to 1,000 jobs across formulation, analytical development, quality operations, regulatory support, documentation, data management, and supply-chain coordination. This job creation potential underscores the facility's importance to regional economic development. With over 12,054 square feet of expansion-ready space, the Fremont site can accommodate additional analytical capacity, expanded development and production workflows, technology-transfer and documentation centers, and functional food and clinical material preparation zones.

This expansion capacity provides flexibility for future growth and adaptation to evolving market demands in both pharmaceutical and functional food sectors. Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized that BioKey serves as an essential pillar of ABVC's global development strategy, providing a fully U.S.-based platform capable of supporting multiple pharmaceutical, botanical, and functional food programs from early formulation through pilot preparation. The facility's domestic location addresses growing concerns about supply chain security and regulatory compliance in pharmaceutical manufacturing. The medium-term development plan targets expanded U.S.-Asia chemistry, manufacturing, and controls execution and increased participation in global pharmaceutical and functional food innovation.

Investors can find detailed information about the company and risk factors in the Company's filings with the Securities and Exchange Commission available at https://www.sec.gov. The facility's multi-product capabilities position it to capitalize on growing demand for both traditional pharmaceuticals and emerging functional food products within a single operational framework. This development represents a strategic response to increasing industry emphasis on domestic manufacturing capabilities and supply chain security, while simultaneously addressing the expanding market for functional foods and nutraceuticals. The integrated approach allows for efficient resource utilization and coordinated development across multiple product categories, potentially reducing time-to-market for new formulations while maintaining rigorous quality standards.